USA flag logo/image

An Official Website of the United States Government

Development of Technologies that Control Scar Contracture after Burn Injuries

Award Information

Agency:
Department of Defense
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
H122-016-0023
Solicitation Year:
2012
Solicitation Topic Code:
DHP12-016
Solicitation Number:
2012.2
Small Business Information
Quick Med Technologies, Inc.
902 NW 4th Street Gainesville, FL -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: Development of Technologies that Control Scar Contracture after Burn Injuries
Agency: DOD
Contract: W81XWH-13-C-0126
Award Amount: $150,000.00
 

Abstract:

Current therapies to prevent scar formation and contracture of burns are minimally effective. QuickMed Technologies (QMT) proposes to develop an advanced therapy to enhance healing and prevent contraction of burn scars by combining the advanced prototype BURN-PLUS dressing with Endoform dermal template. BURN-PLUS is an occlusive island dressing with an adhesive apron bonded onto a super absorbent, microbicidal, pad that provides sustained release of two pre-loaded, FDA-cleared drugs: doxycycline and Kepivance. Doxycycline is a broad spectrum antibiotic that also reduces inflammation through inhibition of tumor necrosis factor alpha (TNFa) converting enzyme (TACE) and inhibits contraction of collagen lattices by myofibroblasts through its inhibition of matrix metalloproteinases (MMPs). Kepivance is keratinocyte growth factor (KGF), which accelerates healing of skin wounds by directly stimulating proliferation and migration of epithelial cells. Endoform is a novel acellular matrix that has intact extracellular matrix (ECM) components (collagen IV, laminin, fibronectin) and growth factors (FGF2, VEGF) that increases vascularization and decreases irregular scar matrix in pig skin wounds. In this Phase I project, QMT will optimize design components of BURN-PLUS dressing and test its effectiveness alone and combined with Endoform matrix on enhancing healing and reducing scar formation and contracture of burn wounds in pigs.

Principal Investigator:

Bernd Liesenfeld
Principal Scientist
(352) 379-0611
bliesenfeld@quickmedtech.com

Business Contact:

Nam Nguyen
Corporate Secretary
(561) 416-1391
nnguyen@quickmedtech.com
Small Business Information at Submission:

Quick Med Technologies, Inc.
902 NW 4th Street Gainesville, FL -

EIN/Tax ID: 980204736
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No